{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:30:20Z","timestamp":1793741420927,"version":"4.6.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.mayocp.2026.07.008","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:33:53Z","timestamp":1784561633000},"page":"2004-2019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Symptoms, Causes, and Treatment of Sarcoidosis"],"prefix":"10.1016","volume":"101","author":[{"given":"Kathryn T.","family":"del Valle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neema","family":"Jayachamarajapura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.mayocp.2026.07.008_bib1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America. Analysis based on health care use","volume":"13","author":"Baughman","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.008_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MCP.0000000000000715","article-title":"Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors","volume":"26","author":"Arkema","year":"2020","journal-title":"Curr Opin Pulm Med"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.008_bib3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/oxfordjournals.aje.a009096","article-title":"Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization","volume":"145","author":"Rybicki","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.008_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1513\/AnnalsATS.201508-568BC","article-title":"Epidemiology of sarcoidosis in a prospective cohort study of US women","volume":"13","author":"Dumas","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"10.1016\/j.mayocp.2026.07.008_bib5","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.200402-249OC","article-title":"A case control etiologic study of sarcoidosis: environmental and occupational risk factors","volume":"170","author":"Newman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.07.008_bib6","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1086\/378097","article-title":"HLA-DRB1\u22171101: a significant risk factor for sarcoidosis in Blacks and Whites","volume":"73","author":"Rossman","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.mayocp.2026.07.008_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102663","article-title":"From genes to granulomas: the genetic blueprint of sarcoidosis","volume":"97","author":"Petrek","year":"2025","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.008_bib8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1164\/rccm.202308-1331LE","article-title":"Genome and transcriptome-wide association study of fibrotic sarcoidosis in European Americans","volume":"209","author":"Liao","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.008_bib9","doi-asserted-by":"crossref","first-page":"00441","DOI":"10.1183\/23120541.00441-2024","article-title":"Family history of pulmonary fibrosis impacts prognosis in patients with sarcoidosis","volume":"11","author":"Plant\u00e9-Bordeneuve","year":"2025","journal-title":"ERJ Open Res"},{"issue":"9","key":"10.1016\/j.mayocp.2026.07.008_bib10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1164\/rccm.201507-1372OC","article-title":"High-density genetic mapping identifies new susceptibility variants in sarcoidosis phenotypes and shows genomic-driven phenotypic differences","volume":"193","author":"Rivera","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.mayocp.2026.07.008_bib11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fimmu.2017.00422","article-title":"SNP variants in major histocompatibility complex are associated with sarcoidosis susceptibility \u2014 a joint analysis in four European populations","volume":"8","author":"Wolin","year":"2017","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.07.008_bib12","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1136\/thoraxjnl-2016-209032","article-title":"Seasonal variation in incidence of sarcoidosis: a population-based study, 1976-2013","volume":"71","author":"Ungprasert","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.mayocp.2026.07.008_bib13","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3389\/fimmu.2018.01516","article-title":"In situ humoral immunity to vimentin in HLA-DRB1\u221703(+) patients with pulmonary sarcoidosis","volume":"9","author":"Kinloch","year":"2018","journal-title":"Front Immunol"},{"issue":"160","key":"10.1016\/j.mayocp.2026.07.008_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2021","article-title":"Epigenetics and sarcoidosis","volume":"30","author":"Konigsberg","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.mayocp.2026.07.008_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103122","article-title":"Genetic predisposition to sarcoidosis","volume":"149","author":"Liao","year":"2024","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.008_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression","volume":"18","author":"Linke","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.mayocp.2026.07.008_bib17","article-title":"Biomarkers and molecular endotypes of sarcoidosis: lessons from omics and non-omics studies","volume":"14","author":"Ji","year":"2023","journal-title":"Front Immunol"},{"issue":"18","key":"10.1016\/j.mayocp.2026.07.008_bib18","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.3390\/diagnostics13182899","article-title":"Pulmonary sarcoidosis and immune dysregulation: a pilot study on possible correlation","volume":"13","author":"Cifaldi","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.008_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.it.2025.01.002","article-title":"The \u201cinflammazone\u201d in chronic inflammatory diseases: psoriasis and sarcoidosis","volume":"46","author":"Saw","year":"2025","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.008_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-025-02566-5","article-title":"The interplay between M2-like macrophages and Th17.1 cells promotes the progression of early-stage sarcoidosis","volume":"24","author":"Zhao","year":"2025","journal-title":"Cell Commun Signal"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.008_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01324-2025","article-title":"Sarcoidosis: a state-of-the-art review","volume":"37","author":"Miedema","year":"2026","journal-title":"Eur Respir J"},{"issue":"10 pt 1","key":"10.1016\/j.mayocp.2026.07.008_bib22","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.mayocp.2026.07.008_bib23","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0002-9343(01)00760-4","article-title":"Hypercalcemia and sarcoidosis \u2014 another piece of the puzzle falls into place","volume":"110","author":"Gardner","year":"2001","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2026.07.008_bib24","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.008_bib25","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1055\/a-2741-2030","article-title":"Biomarkers in sarcoidosis: from traditional markers to precision medicine","volume":"46","author":"Pascual","year":"2025","journal-title":"Semin Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.008_bib26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.rmed.2014.02.002","article-title":"Serial chitotriosidase measurements in sarcoidosis \u2014 two to five year follow-up study","volume":"108","author":"Harlander","year":"2014","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.008_bib27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1023\/B:BOLI.0000043025.17721.fc","article-title":"The expanding spectrum of disorders with elevated plasma chitotriosidase activity: an update","volume":"27","author":"Michelakakis","year":"2004","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.008_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12931-022-01993-z","article-title":"Clinical phenotyping in sarcoidosis using cluster analysis","volume":"23","author":"Lin","year":"2022","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.008_bib29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jcmg.2025.02.010","article-title":"Global practices in cardiac imaging for cardiac sarcoidosis: a survey study of international experts with Delphi consensus","volume":"18","author":"Kafil","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.mayocp.2026.07.008_bib30","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.2022.1570","article-title":"Diagnosis and Treatment of Pulmonary Sarcoidosis: A Review","volume":"327","author":"Belperio","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.008_bib31","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.athoracsur.2016.05.110","article-title":"Endosonography versus mediastinoscopy in mediastinal staging of lung cancer: systematic review and meta-analysis","volume":"102","author":"Sehgal","year":"2016","journal-title":"Ann Thorac Surg"},{"issue":"155","key":"10.1016\/j.mayocp.2026.07.008_bib32","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.008_bib33","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.mayocp.2026.07.008_bib34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S2213-2600(25)00338-8","article-title":"A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders position paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders","volume":"14","author":"Wells","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.008_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of Mortality in Pulmonary Sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.008_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00198-2023","article-title":"High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)","volume":"62","author":"Dhooria","year":"2023","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.008_bib37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.008_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12890-020-01290-9","article-title":"Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study","volume":"20","author":"Kahlmann","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.mayocp.2026.07.008_bib39","first-page":"21","article-title":"Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography","volume":"8","author":"Cheng","year":"2018","journal-title":"Psoriasis (Auckl)"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.008_bib40","article-title":"Response to corticosteroids and alternative therapies in sarcoidosis-related hypercalcemia: a guideline-lacking retrospective analysis","volume":"42","author":"Robinson","year":"2025","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.mayocp.2026.07.008_bib41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejim.2022.12.003","article-title":"Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: a meta-analysis","volume":"109","author":"Rezaee","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"10","key":"10.1016\/j.mayocp.2026.07.008_bib42","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S2213-2600(15)00199-X","article-title":"New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches","volume":"3","author":"Baughman","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.mayocp.2026.07.008_bib43","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/thorax-2025-223014","article-title":"Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis","volume":"80","author":"Bechman","year":"2025","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.mayocp.2026.07.008_bib44","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.chest.2025.09.130","article-title":"Comparative outcomes and side effects of immunosuppressants and tumor necrosis factor inhibitors in sarcoidosis: a real-world data analysis","volume":"169","author":"Chao","year":"2026","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.008_bib45","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.semarthrit.2018.10.005","article-title":"Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety","volume":"48","author":"Adler","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.008_bib46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12931-022-01971-5","article-title":"Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis","volume":"23","author":"Sakkat","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.mayocp.2026.07.008_bib47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S192922","article-title":"Refractory sarcoidosis: a review","volume":"16","author":"El Jammal","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.008_bib48","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.008_bib49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/MCP.0000000000001196","article-title":"New therapeutic options in sarcoidosis","volume":"31","author":"Nunes","year":"2025","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.008_bib50","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"22","key":"10.1016\/j.mayocp.2026.07.008_bib51","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.07.008_bib52","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.chest.2021.05.031","article-title":"A pilot randomized trial of transdermal nicotine for pulmonary sarcoidosis","volume":"160","author":"Crouser","year":"2021","journal-title":"Chest"},{"issue":"30","key":"10.1016\/j.mayocp.2026.07.008_bib53","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1093\/eurheartj\/ehae356","article-title":"Management of cardiac sarcoidosis","volume":"45","author":"Sharma","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mayocp.2026.07.008_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577958","article-title":"Management of neurosarcoidosis","volume":"372","author":"Kidd","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.07.008_bib55","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.008_bib56","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clindermatol.2007.03.010","article-title":"Sarcoidosis and malignancy","volume":"25","author":"Cohen","year":"2007","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.mayocp.2026.07.008_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107640","article-title":"Sarcoid-like reactions to immune checkpoint inhibitors: incidence, treatment course, and impact on cancer progression and survival","volume":"227","author":"Smith","year":"2024","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.008_bib58","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1210\/jc.2012-4197","article-title":"Coexisting primary hyperparathyroidism and sarcoidosis cause increased angiotensin-converting enzyme and decreased parathyroid hormone and phosphate levels","volume":"98","author":"Lim","year":"2013","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626186418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626186418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:00:57Z","timestamp":1793739657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619626186418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0025619626186418"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.07.008","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptoms, Causes, and Treatment of Sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}